Our Board

Our experienced board provides strong oversight and governance

Mr Robert W. Duggan has served as Summit’s Chief Executive Officer since April 2020 and a member of the Board of Directors since December 2019. He is a US-based serial entrepreneur who has built several successful companies across different industries, including biotechnology. Mr Duggan is currently the Chief Executive Officer of Duggan Investments Inc., a private US investment firm. Mr Duggan has served on the boards of a number of US public and private companies and he is currently Chairman of the Board of the Nasdaq listed company, Pulse Biosciences, Inc. He was previously a substantial shareholder in and the Chairman of the Board and Chief Executive Officer of Pharmacyclics, Inc., which was sold to AbbVie Inc., in 2015. Previously, he was the Chairman of the Board and Chief Executive Officer of Computer Motion, Inc., which later merged with Intuitive Surgical, Inc.

Mr. Erdtmann has over 25 years of experience in the investment banking and the financial industries. He currently is a Portfolio Manager and General Partner at Point Sur Investors, a biotech focused investment fund. He also serves as President and co-founder of Biomea Health, a precision oncology company creating new generations of molecular scaffolds of targeting genetically defined diseases. Prior to Biomea Health, Mr. Erdtmann was 8 years at Pharmacyclics, Inc. (NASDAQ: PCYC) and oversaw a broad range of departments while helping to grow the company from 47-634 employees. He began leading the Finance Department and managed all Accounting, SEC Reporting, Audits and Investor Relations. He also built up and ran IT, HR, Legal, Facilities and Events for the company. Later, as the Executive Vice President of Corporate Affairs, he assumed additional responsibilities for Corporate Communications. Mr. Erdtmann actively participated in the final execution of key corporate milestones for Pharmacyclics, among them the Collaboration Agreement with J&J in 2011 (value $1 Billion) and the merger agreement with AbbVie in 2015 (value $21 Billion). Mr. Erdtmann served on the board of PolarityTE (NASDAQ PTE), a regenerative medicine company, where he was it’s Audit Committee Chair until March 2020. Mr. Erdtmann began his career at Commerzbank in Germany, where he was an investment banker and portfolio manager for large institutional accounts. He earned the Diplom Kaufmann degree with honors in finance and banking from the Westfaelische Wilhelms Universitaet of Muenster, Germany, the equivalent to a US Master of Business Administration degree.

Ms. Mahatme has over 30 years of experience in corporate law and financing in a diverse range of companies from start-ups to Fortune 500 companies, including those in the healthcare and biotechnology sector. She is the Founder and Managing Partner of Mahatme Bitterman PLLC, where she focuses on US and international clients in the healthcare/biotechnology, technology and real estate sectors. Previously, Ms. Mahatme served as Counsel at Gibson, Dunn & Crutcher and Counsel and Associate at Pillsbury Winthrop Shaw Pittman LLP. Ms. Mahatme serves on the board of Lakota Children’s Enrichment and was a past board member of the Board of Education, Lake Placid Central School District and Greenacres Association. She received her Bachelor of Commerce (accounting, business, and economics) from Brihan Maharashtra College of Commerce, University of Poona, her Bachelor of Laws (general) from ILS Law School, University of Poona, Master of Laws (general law) from the University of Cambridge and Master of Laws (corporate law) from New York University.

Mr. Manmeet Soni has extensive experience in transitioning biotechnology companies from development stage through commercialisation and globalisation. He is currently the Chief Financial Officer and Executive Vice President of Reata Pharmaceuticals, Inc. where he is responsible for overall global functions of finance, tax, treasury, internal audit, information technology, investor relations, corporate communication and strategy functions. He has served as the Chief Financial Officer of several publicly-listed life science companies, including Pharmacyclics, Inc., where he played a vital role in the acquisition by Abbvie, Inc. for $21 billion in 2015, Ariad Pharmaceuticals Inc., where he played a major role in the acquisition by Takeda Inc. for $5.1 billion in 2017, and Alnylam Pharmaceuticals, Inc., where he raised over $2.5 billion in cash. Mr. Soni currently serves on the board of Arena Pharmaceuticals, Inc. and Pulse Biosciences, Inc. He is a certified public accountant and chartered accountant from India and received his Bachelor of Commerce from Hansraj College, Delhi University, India.

Dr. Zanganeh is Founder/CEO of Maky Zanganeh and Associates, which provides consulting services to businesses in product development, research and transactions. She has more than 15 years of management, corporate, clinical, and business experience in the pharmaceutical, medical device and technology industries.

Most recently, Dr. Zanganeh was Chief Operating Officer at Pharmacyclics Inc. where she oversaw all clinical, research, commercial and business-related matters. Under her leadership, the company was able to achieve four FDA labels, with three Breakthrough Therapy Designations, in 14 months; a feat which has never been accomplished by any company before.   Dr. Zanganeh also drove the multimillion dollar collaboration and license deal for ibrutinib with Janssen Biotech Inc. in 2011 and the subsequent sale of the company for $21 billion dollars in 2015 to Abbvie Inc.; the second largest biopharma sale ever in the industry.  The deal with Janssen Biotech received the award of the “Best Biotech Transaction” in 2011

Previously (2003-2008), she held senior positions of increasing responsibility within companies such as Robert Duggan & Associates (a private investment firm), President of EMEA / Global VP of Training and Education for Computer Motion, Inc. (Pioneers in Robotic Surgery). Computer Motion, Inc. merged with Intuitive Surgical (ISRG) company in June 2003.

Dr. Zanganeh was awarded her D.D.S. from the Louis Pasteur University, France and an MBA from Schiller International University, France. She is fluent in French, German, Farsi and English. Dr Zanganeh earned the Fierce Biotech “2013 Top women in biotech” award and the E&Y company,  Entrepreneur of the Year 2013 award.

Dr. Zanganeh is an active board member for the following companies: Pulse BioScience, RenovoRx.